[Edaily Reporter Park Jeong-soo] #Prestige Biologics announced on the 10th that it has signed a contract for the contract manufacturing of active pharmaceutical ingredients (APIs) worth 2.66643 billion won. The contract amount represents 21.27% of last year’s revenue, and the contract period runs until March 31 of next year. The identity of the contracting party was not disclosed at the request of the other party to maintain confidentiality. The confidentiality period extends until the end of March next year.
Disclosure Plus
Prestige Biologics Signs 2.7 Billion Won Contract for Contract Manufacturing of Active Pharmaceutical Ingredients
Economy
Corporation
IT·Science
Economy
Government Boosts Hostile M&As, While Pension Funds Draw the Line
Although the government has played the “hostile M&A” card to put pressure on undervalued companies, there are significant obstacles preventing a vigorous competition for management control. This is du…
Corporation
SamyangFoods’ Holding Company Establishes Wind Power Subsidiary in Pyeongchang… Pursuing New Mid- to Long-Term Business Ventures
Samyang Round Square, the holding company of SamyangFoods(003230), has established a wind power generation subsidiary in Pyeongchang, Gangwon Province. This move is intended to pursue a “repowering” p…
IT·Science
BEXCO is Already Hosting 'G-STAR'… PearlAbyss Corp.'s 'Red Desert' Wins Daesang
With the opening of “G-STAR 2026,” Korea’s largest game exhibition, just one day away, all eyes in the gaming industry are on the event. Moving away from past exhibitions that primarily featured new t…